Identification of SDC1 as a Key Regulator and Therapeutic Target in Rheumatoid Arthritis via JAK2 ‐ STAT3 Pathway
International Journal of Rheumatic Diseases · 2026
DOI: 10.1111/1756-185x.70524 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Gan Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Laboratory Department, Baoding No. 1 Central Hospital, Baoding City, Hebei Province, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Arthritis, Rheumatoid, Arthritis, Experimental, Janus Kinase 2. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder with unclear molecular mechanisms, complicating early diagnosis and treatment. This study aimed to identify hub genes and pathways driving RA pathogenesis and assess their therapeutic potential.
Methods
Gene expression datasets related to RA were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified and analyzed by functional enrichment and protein–protein interaction network construction. Machine learning approaches, including LASSO regression, random forest, and SVM‐RFE, were used to screen hub genes. Pathway associations were explored using Gene Set Enrichment Analysis (GSEA). Experimental validation was performed in collagen‐induced arthritis (CIA) rat models and MH7A synovial fibroblast cells through Western blot and functional assays.
Results
A total of 106 DEGs were identified in RA synovial tissues, including 76 upregulated and 30 downregulated genes. Enrichment analyses revealed involvement in cytokine–cytokine receptor interaction, lymphocyte‐mediated immunity, and immunoglobulin complexes. SDC1 emerged as a key hub gene across all three machine learning methods. GSEA indicated its significant correlation with the JAK–STAT pathway. In CIA rats, SDC1 expression was markedly elevated alongside p‐JAK2 and p‐STAT3 levels. Silencing SDC1 in MH7A cells reduced cell proliferation, decreased p‐JAK2 and p‐STAT3 expression, and promoted apoptosis.
Conclusions
This study identifies SDC1 as a central hub gene in RA pathogenesis through activation of the JAK2–STAT3 signaling pathway. These findings highlight SDC1 as a potential biomarker for early diagnosis and a promising target for therapeutic intervention, providing new insights into RA management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Laboratory Department, Baoding No. 1 Central Hospital, Baoding City, Hebei Province, China.
- The Pathology Department, Xi'an Chest Hospital, Xi'an City, Shanxi Province, China.
ORCID-Profile: Gan Cao
Förderung
- Natural Science Foundation of Hebei Province
Zitieren
APA
Cao, G., Wu, Z., Du, Y., Dai, D., Sun, Y., Jia, X., & Cai, H. (2026). Identification of SDC1 as a Key Regulator and Therapeutic Target in Rheumatoid Arthritis via JAK2 ‐ STAT3 Pathway. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70524
Vancouver
Cao G, Wu Z, Du Y, Dai D, Sun Y, Jia X, et al. Identification of SDC1 as a Key Regulator and Therapeutic Target in Rheumatoid Arthritis via JAK2 ‐ STAT3 Pathway. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70524
BibTeX
@article{Cao2026,
author = {Cao, Gan and Wu, Zhihui and Du, Yatao and Dai, Dongxue and Sun, Yang and Jia, Xi and Cai, Huixin},
title = {Identification of SDC1 as a Key Regulator and Therapeutic Target in Rheumatoid Arthritis via JAK2 ‐ STAT3 Pathway},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
doi = {10.1111/1756-185x.70524}
}
EUVIMED